Guideline Summary for Testosterone Therapy in Postmenopausal Women with Hypoactive Sexual Desire Disorder (HSDD)

Indication

• Testosterone therapy should be offered only to postmenopausal women who have a formally diagnosed HSDD after a comprehensive biopsychosocial assessment, as the condition is the sole evidence‑based indication for use in this population. 1

Formulation Selection

• When female‑specific testosterone products are unavailable, off‑label use of male‑approved transdermal formulations at reduced doses is acceptable, provided serum testosterone concentrations remain within the physiologic female range. 1
• Compounded “bioidentical” testosterone preparations should be avoided unless no authorized equivalent exists, because efficacy and safety data are insufficient. 1
• Supraphysiologic delivery methods (e.g., pellets, intramuscular injections) are not recommended because they produce excessive testosterone levels. 1

Initiation & Monitoring Protocol

• Initial monitoring: Measure total testosterone 3–6 weeks after starting therapy to confirm absorption and guide dose adjustments. 1
• Long‑term monitoring: Check serum total testosterone every 6 months to detect overuse and ensure levels stay within the physiologic premenopausal range. 1
• At each follow‑up visit, assess for signs of androgen excess (e.g., acne, hirsutism, voice deepening, clitoromegaly). 1
• If no clinical benefit in sexual function is observed by 6 months, discontinue testosterone therapy. 1

Safety and Contraindications

• Absolute contraindications include pregnancy, hormone‑sensitive breast or uterine cancer, and active cardiovascular disease. 1
• Clinical trials of up to 24 months have shown that physiologic‑dose testosterone in postmenopausal women is not associated with serious adverse events. 1
• Evidence beyond 24 months is lacking; long‑term effects on cardiovascular health, cancer risk, and cognition remain unknown. 1
• Most trials excluded women with high cardiometabolic risk and required concurrent estrogen therapy, limiting applicability to higher‑risk populations. 1

Practical Pitfalls to Avoid

• Do not use male‑formulated testosterone gels at typical male doses (≈50–100 mg daily) in women, as this yields supraphysiologic testosterone levels and raises adverse‑effect risk. 1
• Do not continue therapy beyond 6 months without documented improvement in sexual function, as prolonged exposure without benefit is unjustified. 1

Testosterone Gel Therapy for Postmenopausal Women with Hypoactive Sexual Desire Disorder (HSDD)

Indications

• The only evidence‑based indication for testosterone therapy in women is the treatment of HSDD in postmenopausal women after a formal biopsychosocial assessment. [@1]

Starting Dose & Target Serum Levels

• Initiate therapy with 5 mg of testosterone gel applied daily to the upper arm or outer thigh, aiming for serum total testosterone in the mid‑to‑high premenopausal range (≈30–50 ng/dL). [@1, @2]

Formulation Selection

• When a female‑specific testosterone product is unavailable, off‑label use of an approved male formulation is acceptable provided the resulting hormone concentrations remain within the physiologic female range. [@1]
• Compounded “bioidentical” testosterone preparations are not recommended due to insufficient efficacy and safety data, unless no authorized equivalent is accessible. [@1]

Baseline Assessment

• Obtain a baseline total testosterone measurement before starting therapy. [@1, @2]

Initial Follow‑Up (3–6 Weeks)

• Repeat total testosterone 3–6 weeks after initiation to verify absorption and guide any dose adjustment. [@1, @2]

Long‑Term Monitoring (Every 6 Months)

• Evaluate clinical response and screen for signs of androgen excess (e.g., acne, hirsutism, voice deepening, clitoromegaly) with serum testosterone measurement at 6‑month intervals. [@1, @2]
• Discontinue therapy if no clinical benefit is observed by 6 months. [@1]

Safety & Contraindications

• Absolute contraindications: pregnancy, breast cancer, and active cardiovascular disease. [@1, @2]
• Routine hematocrit monitoring is not required for women receiving these low doses, unlike in male patients. [@2]

Consensus Recommendations

• The 2019 Global Consensus Statement recommends against testosterone preparations that produce supraphysiologic concentrations, such as pellets and injections. [@1]

Common Pitfalls to Avoid

• Do not use male‑formulated testosterone gels at male doses (≈50–100 mg daily); this yields supraphysiologic levels in women and raises adverse‑effect risk. [@1]
• Do not prescribe testosterone for indications other than HSDD (e.g., bone health, cognition, energy, well‑being) because efficacy and long‑term safety are unproven. [@2]
• Do not continue therapy beyond 6 months without improvement in sexual function, as prolonged exposure without benefit is unjustified. [@1]

Topical Testosterone Cream for Postmenopausal Women with HSDD

Indication and Patient Selection

• Testosterone therapy in women is evidence‑based only for treating hypoactive sexual desire disorder (HSDD) after a comprehensive biopsychosocial assessment in postmenopausal patients. 2, 3
• Testosterone should not be prescribed for bone health, cognitive function, energy, general well‑being, cardiovascular health, or metabolic dysfunction in women because efficacy and long‑term safety data are lacking. 3
• Absolute contraindications include pregnancy, hormone‑sensitive breast or uterine cancer, and active cardiovascular disease. 2

Formulation and Dosing

• No FDA‑approved female‑specific testosterone product exists in the United States; off‑label use of a male‑approved transdermal gel is acceptable provided serum testosterone remains within the physiologic female range. 2, 3
• A reduced dose of approximately 5 mg of testosterone gel applied daily to the upper arm or outer thigh restores total testosterone to the mid‑to‑high premenopausal range (≈30–50 ng/dL) and free testosterone within the premenopausal range. 2
• Compounded “bioidentical” testosterone preparations should be avoided unless no authorized equivalent is available, because efficacy and safety data are insufficient. 2, 3
• Supraphysiologic delivery methods such as pellets or intramuscular injections are not recommended because they produce excessive testosterone levels. 2, 3

Baseline Assessment

• Obtain a baseline total testosterone measurement before initiating therapy. 2, 3

Monitoring Protocol

Initial Follow‑Up (3–6 Weeks)

• Repeat total testosterone 3–6 weeks after starting treatment to verify absorption and guide dose adjustment, aiming for serum total testosterone 30–50 ng/dL. 2, 3

Long‑Term Monitoring (Every 6 Months)

• Evaluate clinical response (improvement in sexual desire, frequency, receptivity, and initiation) and screen for signs of androgen excess (acne, hirsutism, voice deepening, clitoromegaly) while measuring serum testosterone. 2, 3
• Discontinue therapy if no clinical benefit is observed by 6 months, as prolonged exposure without benefit is unjustified. 2, 3

Safety and Duration

• Clinical trials of up to 24 months have shown that physiologic‑dose testosterone in postmenopausal women is not associated with serious adverse events. 2
• Evidence beyond 24 months is lacking; long‑term effects on cardiovascular health, cancer risk, and cognition remain unknown. 2
• Most trials excluded women with high cardiometabolic risk and required concurrent estrogen therapy, limiting applicability to higher‑risk populations. 2

Common Pitfalls to Avoid

• Do not use male‑formulated testosterone gels at typical male doses (≈50–100 mg daily), as this yields supraphysiologic testosterone levels in women and raises adverse‑effect risk. 2
• Do not continue therapy beyond 6 months without documented improvement in sexual function. 2
• Do not prescribe testosterone for indications other than HSDD (e.g., bone health, cognition, energy, well‑being) because efficacy and long‑term safety are unproven. 3

Topical Testosterone Therapy for Postmenopausal Women with Hypoactive Sexual Desire Disorder

Indication and Contraindications

• Testosterone should be prescribed only for postmenopausal women with a formally diagnosed hypoactive sexual desire disorder (HSDD) after a comprehensive biopsychosocial assessment; this is the sole evidence‑based indication. 4
• Testosterone is not indicated for bone health, cognition, energy, general well‑being, or metabolic dysfunction because efficacy and long‑term safety are unproven for these uses. 4
• Absolute contraindications include pregnancy, hormone‑sensitive breast or uterine cancer, and active cardiovascular disease. 4

Recommended Formulation and Dosing

• Off‑label use of male‑approved transdermal gels (e.g., AndroGel 1 %, AndroGel 1.62 %, Testim 1 %, Fortesta 2 %, Axiron 2 %) at approximately one‑tenth the male dose (≈5 mg daily) applied to the upper arm or outer thigh achieves physiologic female testosterone levels of 30–50 ng/dL. 4
• The preferred regimen is 5 mg of a male‑approved gel daily (e.g., 0.25 mL of AndroGel 1.62 % or one‑tenth of a 50 mg Testim packet) applied to clean, dry skin; hands must be washed immediately and the site covered to prevent transfer. 4
• Baseline total testosterone should be obtained before initiating therapy to confirm a pre‑treatment level within the expected low‑female range. 4

Monitoring and Follow‑up

• Initial monitoring (3–6 weeks): repeat total testosterone to verify absorption and adjust dose to maintain serum levels of 30–50 ng/dL; dose adjustments are made in 2.5 mg increments. 4
• Long‑term monitoring (every 6 months): assess clinical response (improvement in sexual desire, frequency, receptivity, initiation) and screen for signs of androgen excess (acne, hirsutism, voice deepening, clitoromegaly) with concurrent serum testosterone measurement. Discontinue therapy if no clinical benefit is observed by 6 months. 4
• Hematocrit monitoring is not required for women receiving physiologic‑dose testosterone, unlike in male patients. 4

Safety and Efficacy Evidence

• Clinical trials of up to 24 months demonstrate that physiologic‑dose testosterone in postmenopausal women is not associated with serious adverse events. 4
• Evidence beyond 24 months is lacking; long‑term effects on cardiovascular health, cancer risk, and cognition remain unknown. 4
• Most trials excluded women with high cardiometabolic risk and required concurrent estrogen therapy, limiting applicability to higher‑risk populations. 4

Avoided Formulations and Common Pitfalls

• Compounded “bioidentical” testosterone creams should be avoided unless no authorized equivalent exists, because efficacy and safety data are insufficient and pharmacy‑to‑pharmacy quality control is inconsistent. 5
• If a compounded product is unavoidable, it must meet active‑pharmaceutical‑ingredient purity standards and Good Manufacturing Practice, with dosing limited to achieve physiologic premenopausal testosterone concentrations. 4
• Testosterone pellets and intramuscular injections are not recommended because they produce supraphysiologic levels that cannot be easily adjusted and increase the risk of virilization. 4
• Testosterone patches (Androderm) are male‑formulated, deliver doses too high for women, and frequently cause significant skin irritation. 6
• Do not use male‑formulated gels at typical male doses (≈50–100 mg daily); such dosing yields supraphysiologic testosterone levels in women and raises the risk of irreversible virilization. 4
• Do not continue therapy beyond 6 months without documented improvement in sexual function; prolonged exposure without benefit is unjustified. 4
• Do not prescribe commercially manufactured male testosterone products without dose reduction; the standard male dose is 10–20 times higher than the physiologic female dose. 4
• Avoid compounded preparations when FDA‑approved male formulations can be used off‑label at reduced doses, as compounded products lack standardized potency and quality control. [5][4]